Purpose of the development: The integral test system can be used for the simultaneous quantitative determination of fibrinogen, soluble fibrin and D-dimer in human plasma.

Recommended application field: The medicine. Cardiology, surgery, obstetrics, oncology, endocrinology.

Technical characteristic: High sensitivity (0.5 ± 0.1 µg / ml); specificity (98%), speed of analysis - 3 hours; automatic quantification of parameters; long storage time. Positive results of testing the test system in the leading clinics of Ukraine were obtained.

Advantages over analogues: There are no analogues in the world. In contrast to the well-known similar test systems that use expensive commercial antibodies, the proposed test system uses highly specific monoclonal antibodies of its own production.

The development stage readiness: Ready for application

Description of the development:
()
The integral test system is used to comprehensively diagnose the state of the hemostatic system, identify or eliminate the risk, or the presence of thrombosis in various pathologies in the early stages of the disease, monitor antithrombotic and fibrinolytic therapy, including in cardiological, surgical, obstetric, combustiological, oncological and endocrinological practice .

Information about newness of the development:
there are Ukrainian patents -- 4 items

corresponds technical description
Ready for implementation

Possibility of transfer abroad:
Combinated reduction to industrial level

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua